US · PETS · SPECIALTY RETAIL
PetMed Express, Inc. (PETS) intrinsic value and stock valuation
$0.85as of 2026-11-21 · Mkt cap 42.1M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
PetMed Express, Inc. DCF and intrinsic value
InvestorsCraft values PETS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PETS’s statements →
PetMed Express, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $179M | $227M | $274.1M | $256.6M | $273.4M |
| Operating income | -$-31.41M | -$-1.53M | -$-6.96M | $6.55M | $25.7M |
| Net income | -$-57.29M | -$-6.27M | -$-7.46M | $5.14M | $21.1M |
| EPSd | -$-2.74M | -$-304.37K | -$-365.69K | $252.7K | $1.04M |
| Operating cash flow | -$-28.39M | $4.72M | $4.32M | $27.8M | $18.5M |
| Capital expenditure | -$-4.62M | -$-5.11M | -$-4.51M | -$-5.26M | -$-1.75M |
| Free cash flow | -$-33.01M | -$-400K | -$-190K | $22.5M | $16.8M |
| Total assets | $81.2M | $148.7M | $169.9M | $170M | $176.3M |
| Total debt | $540K | $1M | $1.45M | $990K | $0.00 |
| Net debt | -$-20.88M | -$-53.72M | -$-53.84M | -$-103.09M | -$-111.08M |
| Total equity | $28.9M | $85.1M | $96.7M | $110M | $142.2M |
| Cash and short-term investments | $21.4M | $54.7M | $55.3M | $104.1M | $111.1M |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $179M | $227M | $274.1M | $256.6M | $273.4M |
| Cost of revenue | $138.2M | $157.8M | $196.4M | $185.8M | $198.1M |
| Gross profit | $40.8M | $69.1M | $77.7M | $71M | $75.3M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $72.2M | $62.4M | $79.8M | $68.9M | $49.6M |
| Other expenses | $0.00 | $8.24M | $4.92M | -$-4.21M | $0.00 |
| Operating expenses | $72.2M | $70.7M | $84.7M | $64.7M | $49.6M |
| Cost and expenses | $210.4M | $228.5M | $281.1M | $250M | $247.7M |
| Interest income | $510K | $0.00 | $510K | $450K | $340K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $9.39M | $7.04M | $7.06M | $3.55M | $2.74M |
| Ebitda | -$-22.03M | $6.71M | $780K | $11M | $29.8M |
| Operating income | -$-31.41M | -$-1.53M | -$-6.96M | $6.55M | $25.7M |
| Total other income/expenses, net | -$-25.94M | $940K | $690K | $890K | $1.36M |
| Income before tax | -$-57.36M | -$-590K | -$-6.27M | $7.45M | $27.1M |
| Income tax expense | -$-70K | $5.68M | $1.19M | $2.31M | $5.97M |
| Net income | -$-57.29M | -$-6.27M | -$-7.46M | $5.14M | $21.1M |
| Weighted average shares outstanding | $20.9M | $20.6M | $20.4M | $20.3M | $20.2M |
| Weighted average diluted shares outstanding | $20.9M | $20.6M | $20.4M | $20.3M | $20.4M |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $21.4M | $54.7M | $55.3M | $104.1M | $111.1M |
| Net receivables | $1.91M | $2.32M | $3.28M | $1.74M | $1.91M |
| Inventory | $13.6M | $16.2M | $28.6M | $19M | $32.5M |
| Total current assets | $43.6M | $78.9M | $93.7M | $130.4M | $151M |
| Property, plant and equipment, net | $26.8M | $29.8M | $28.1M | $26.2M | $24.5M |
| Goodwill and intangible assets | $10.8M | $40M | $37.9M | $5.86M | $860K |
| Long-term investments | $5.3M | $0.00 | $5.3M | $5M | $24.3M |
| Total non-current assets | $37.6M | $69.8M | $76.2M | $39.6M | $25.3M |
| Total assets | $81.2M | $148.7M | $169.9M | $170M | $176.3M |
| Accounts payable | $20.9M | $23.6M | $37M | $25.2M | $27.5M |
| Short-term debt | $490K | $460K | $460K | $0.00 | $0.00 |
| Deferred revenue | $690K | $2.08M | $2.6M | $0.00 | $0.00 |
| Total current liabilities | $52M | $62.8M | $72.2M | $57.5M | $33.2M |
| Long-term debt | $40K | $540K | $990K | $990K | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $220K | $800K | $990K | $2.53M | $940K |
| Capital lease obligations | $40K | $0.00 | $990K | $990K | $0.00 |
| Total liabilities | $52.3M | $63.6M | $73.2M | $60M | $34.1M |
| Common stock | $20K | $20K | $20K | $20K | $20K |
| Retained earnings | $9.26M | $66.5M | $71.6M | $91.7M | $130.5M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $28.9M | $85.1M | $96.7M | $110M | $142.2M |
| Total investments | $5.3M | $0.00 | $5.3M | $5M | $24.3M |
| Total debt | $540K | $1M | $1.45M | $990K | $0.00 |
| Net debt | -$-20.88M | -$-53.72M | -$-53.84M | -$-103.09M | -$-111.08M |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | -$-57.29M | -$-6.27M | -$-7.46M | $230K | $21.1M |
| Depreciation and amortization | $9.39M | $7.04M | $7.06M | $3.55M | $2.74M |
| Stock-based compensation | $1.36M | -$-6.59M | $6.87M | $6.62M | $4.55M |
| Change in working capital | -$-8.39M | $3.72M | -$-2.76M | $13.9M | -$-9.71M |
| Accounts receivable | $450K | $600K | -$-1.74M | -$-40K | $510K |
| Inventory | $470K | $12.4M | -$-6.42M | $13.4M | $1.97M |
| Accounts payable | -$-2.66M | -$-13.46M | $6.1M | -$-2.29M | -$-12.05M |
| Net cash provided by operating activities | -$-28.39M | $4.72M | $4.32M | $27.8M | $18.5M |
| Investments in property, plant and equipment | -$-4.62M | -$-5.11M | -$-4.51M | -$-5.26M | -$-1.75M |
| Acquisitions, net | $0.00 | $0.00 | -$-36.16M | -$-5M | $0.00 |
| Net cash used for investing activities | -$-4.62M | -$-5.11M | -$-40.67M | -$-10.26M | -$-1.75M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-20K | -$-180K | -$-12.44M | -$-24.54M | -$-24.38M |
| Net cash used for financing activities | -$-300K | -$-180K | -$-12.44M | -$-24.54M | -$-24.38M |
| Net change in cash | -$-33.31M | -$-580K | -$-48.79M | -$-6.99M | -$-7.64M |
| Cash at end of period | $21.4M | $54.7M | $55.3M | $104.1M | $111.1M |
| Operating cash flow | -$-28.39M | $4.72M | $4.32M | $27.8M | $18.5M |
| Capital expenditure | -$-4.62M | -$-5.11M | -$-4.51M | -$-5.26M | -$-1.75M |
| Free cash flow | -$-33.01M | -$-400K | -$-190K | $22.5M | $16.8M |
Line items
Line items
Line items
About PetMed Express, Inc.
PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and other essential supplies for canines, felines, and equines. Their non-prescription offerings include products for flea and tick prevention, joint and bone care, vitamins, treats, nutritional supplements, hygiene essentials, and general pet supplies. For prescription needs, they supply heartworm and flea/tick preventatives, alongside medications for conditions such as arthritis, dermatitis, thyroid imbalances, diabetes, pain relief, and cardiovascular issues, often providing generic alternatives. Beyond pharmaceuticals, the company also retails pet food, bedding, crates, stairs, and various other accessories. PetMed Express engages with its clientele through multiple distribution channels: its official website, a dedicated mobile application, a telephone contact center, direct mail campaigns (like brochures and postcards), and television advertisements, frequently promoting its 1-800-PetMeds and PetMeds brands. The company was established in 1996 and is headquartered in Delray Beach, Florida.
- CEO
- Leslie C. G. Campbell
- Employees
- 189
- Beta
- 0.78
Included in
Explore
Frequently asked questions
What is the intrinsic value of PetMed Express, Inc. (PETS)?
InvestorsCraft does not currently publish an intrinsic value for PETS. How the IC value is calculated.
Is PETS undervalued?
InvestorsCraft does not publish an undervaluation signal for PETS at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.